12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
Epistemonikos ID: c949e27a4efbbb558f55d55b528014cd460f77f7
First added on: May 21, 2024